Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future

Risk-reducing salpingo-oophorectomy is currently regarded as the most certain primary method for preventing ovarian cancer among BRCA1/2 mutation carriers with hereditary breast and ovarian cancer syndrome. However, risk-reducing salpingo-oophorectomy has rarely been performed in Japan. We developed...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of clinical oncology 2013-05, Vol.43 (5), p.515-519
Main Authors: Hirasawa, Akira, Masuda, Kenta, Akahane, Tomoko, Tsuruta, Tomohiko, Banno, Kouji, Makita, Kazuya, Susumu, Nobuyuki, Jinno, Hiromitsu, Kitagawa, Yuko, Sugano, Kokichi, Kosaki, Kenjiro, Aoki, Daisuke
Format: Article
Language:English
Subjects:
Adult
BRCA1 Protein - genetics
BRCA2 Protein - genetics
Breast Neoplasms - genetics
Breast Neoplasms - prevention & control
Female
Genetic Counseling
Genetic Predisposition to Disease
Genetic Testing
Hereditary Breast and Ovarian Cancer Syndrome - genetics
Hereditary Breast and Ovarian Cancer Syndrome - prevention & control
Heterozygote
Humans
Insurance Coverage
Japan
Middle Aged
Mutation
Ovarian Neoplasms - genetics
Ovarian Neoplasms - prevention & control
Ovariectomy - economics
Pedigree
Risk Factors
Risk Reduction Behavior
Salpingectomy - economics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Risk-reducing salpingo-oophorectomy is currently regarded as the most certain primary method for preventing ovarian cancer among BRCA1/2 mutation carriers with hereditary breast and ovarian cancer syndrome. However, risk-reducing salpingo-oophorectomy has rarely been performed in Japan. We developed the first system in Japan for performing risk-reducing salpingo-oophorectomy for BRCA1/2 mutation carriers at our university hospital in 2008. The indication for risk-reducing salpingo-oophorectomy for patients with hereditary breast/ovarian cancer syndrome is currently limited in Japan. This situation may be because of the limited number of genetic counseling units, the limited number of facilities that can perform BRCA1/2 genetic testing and the fact that prophylactic surgery is not covered by health insurance in Japan. Recent treatment guidelines for breast cancer in Japan recommended risk-reducing salpingo-oophorectomy for BRCA1/2 mutation carriers. Risk-reducing salpingo-oophorectomy should be performed in the framework of the standard therapeutic modality for BRCA1/2 mutation carriers in the near future.
ISSN:0368-2811
1465-3621
DOI:10.1093/jjco/hyt036